PROLOR Biotech To Present At Jefferies 2013 Global Healthcare Conference
NES-ZIONA, Israel, May 31, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Jefferies 2013 Global Healthcare Conference, being held at the Grand Hyatt Hotel in New York City. The presentation is scheduled for June 4, 2013 at 4:30 pm ET.
A live webcast of the company's presentation will be available at the Investors section of PROLOR's website at www.prolor-biotech.com/?CategoryID=215, or at http://wsw.com/webcast/jeff77/pbth/. An audio replay of the presentation will be available on the PROLOR website approximately one hour after the presentation and will be archived for at least 30 days.
The Jefferies 2013 Global Healthcare Conference will be held June 3-6, 2013. For more information, visit http://www.jefferies.com/OurFirm/Conferences/325/70.
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is developing a long-acting version of human growth hormone, which is currently being assessed in a Phase III pivotal trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development. For more information, visit www.prolor-biotech.com.
SOURCE PROLOR Biotech, Inc.